Bank OZK (OZK) Income Statement

Net interest income peaked at $413.9M in 2025Q3 and has since contracted for three consecutive quarters, with 2026Q2 at $392.1M. This deceleration appears driven by the rapidly increasing cost of interest-bearing deposits, as flagged in recent context, which is outpacing the repricing benefits of the floating-rate construction loan portfolio. The sequential decline from 2025Q4's $407.0M to 2026Q2's $392.1M indicates that deposit beta is now a binding constraint on NII growth, even as the RESG pipeline remains active. Investors should monitor whether the bank can pass through higher funding costs via new loan origination yields or if NII will continue to erode.

The NIM decline from 1.1% to 0.9% over eight quarters is modest in absolute terms but significant for a bank whose profitability hinges on spread income. The efficiency ratio has improved to 25.4% in 2026Q2 from 20.0% in 2024Q1, indicating that expense discipline is partially offsetting margin pressure. However, the NIM trend suggests that the bank's low-cost deposit advantage is eroding as competition for funding intensifies. If deposit costs continue to rise without commensurate loan yield increases, the NIM could fall below 0.9%, pressuring returns on equity.

The efficiency ratio has risen by nearly 600 basis points over the past two years, driven by a combination of slower revenue growth and fixed cost increases. While the absolute ratio remains best-in-class among peers—IBOC sits at 49.4% and HOMB at 43.8%—the trajectory is concerning. The bank's investment in its Labs division and specialized RESG personnel appears to be adding to the cost base without yet generating proportional revenue. If revenue growth remains subdued, the efficiency ratio could continue to climb, eroding the bank's historical cost advantage.

The provision expense has been volatile, ranging from $35.2M to $50.6M over the past eight quarters, with no clear trend until the recent uptick. The increase in 2026Q2 may reflect management's forward-looking economic assumptions under CECL, particularly for the new life sciences and medical office verticals, which carry different risk profiles than traditional construction. The bank's weighted average LTV remains conservative, but the concentration in gateway cities like San Francisco and New York introduces idiosyncratic risk. If credit quality deteriorates, provision expenses could rise further, directly impacting net income.

Fee income has grown from $28.8M in 2024Q2 to $37.9M in 2026Q2, a 31.6% increase, but it still represents a small fraction of the revenue mix. The volatility in fee income—ranging from $28.8M to $37.9M—suggests it is driven by transaction-based activities like loan syndications rather than recurring wealth management fees. This dependency on NII makes the bank more sensitive to interest rate cycles than diversified peers. Investors should watch whether the Labs division can generate scalable fee-based revenue, but current data suggests it remains immaterial.

The 2026Q2 results represent a clear departure from the prior two years of steady growth. NII declined year-over-year for the first time in the series, and the absence of forward guidance from management adds uncertainty. The combination of rising provision expenses, a shrinking NIM, and a higher efficiency ratio indicates that the bank's historical growth model is facing headwinds. This period may mark the beginning of a slower growth phase, particularly if the RESG pipeline's unfunded commitments do not convert to earning assets at the same pace. Investors should monitor upcoming quarters for signs of stabilization or further deterioration.